Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

msh id	COM:EXACTSCIENCES
symbol	EXAS
name	Exact Sciences Corporation
homepage url	https://www.exactsciences.com
country	US
sector	Healthcare
industry	Medical - Diagnostics & Research
market	STOCKS
employee count	6.5K
crunchbase url	-
linkedin url	-
founders	-

market cap	8.36B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.02
growth cost of revenue	0.14
growth depreciation and amortization	1.12
growth ebitda	0.97
growth ebitda ratio	0.98
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.92
growth gross profit	0.22
growth gross profit ratio	0.02

COM:EXACTSCIENCES

Exact Sciences Corp

Last Close

52.70

21/11 21:00

Market Cap

8.36B

Beta: -

Volume Today

2.37M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	2.71B
cost of revenue	2.71B
depreciation and amortization	206.61M
ebitda	-13.13M
ebitda ratio	-0.01
eps	-1.13
eps diluted	-1.13
operating expenses	2.06B
operating income	-215.01M
operating income ratio	-0.09

accounts receivables	-43.42M
capital expenditure	-124.19M
cash at beginning of period	242.79M
cash at end of period	609.68M
inventory	127.48M
working capital ttm	671.67M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-